Distinct Genomic Aberrations between Low-Grade and High-Grade Gliomas of Chinese Patients by Li, Y et al.
Distinct Genomic Aberrations between Low-Grade and
High-Grade Gliomas of Chinese Patients
Yunbo Li1,4., Dapeng Wang2*., Lei Wang2.¤, Jinhai Yu1, Danhua Du1, Ye Chen3, Peng Gao1, Duen-
Mei Wang2, Jun Yu2, Feng Zhang2,5*, Shuanglin Fu1*
1 First Hospital of Jilin University, Changchun, PR China, 2CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of
Sciences, Beijing, PR China, 3Norman Bethune College of Medicine, Jilin University, Changchun, PR China, 4 Jilin University, Changchun, PR China, 5Northeast Normal
University, Changchun, PR China
Abstract
Background: Glioma is a type of tumor that develops in the central nerve system, mainly the brain. Alterations of genomic
sequence and sequence segments (such as copy number variations or CNV and copy neutral loss of heterozygosities or
cnLOH) are thought to be a major determinant of the tumor grade.
Methods: We mapped genomic variations between low-grade and high-grade gliomas (LGG and HGG) in Chinese
population based on Illumina’s Beadchip and validated the results using real-time qPCR.
Results: At the cytoband level, we discovered: (1) unique losses in LGG on 5q, 8p and 11q, and in HGG on 6q, 11p, 13q and
19q; (2) unique gains in the LGG on 1p and in HGG at 5p, 7p, 7q and 20q; and (3) cnLOH in HGG only on 3q, 8q, 10p, 14q,
15q, 17p, 17q, 18q and 21q. Subsequently, we confirmed well-characterized oncogenes among tumor-related loci (such as
EGFR and KIT) and detected novel genes that gained chromosome sequences (such as AASS, HYAL4, NDUFA5 and SPAM1) in
both LGG and HGG. In addition, we found gains, losses, and cnLOH in several genes, including VN1R2, VN1R4, and ZNF677, in
multiple samples. Mapping grade-associated pathways and their related gene ontology (GO) terms, we classified LGG-
associated functions as ‘‘arachidonic acid metabolism’’, ‘‘DNA binding’’ and ‘‘regulation of DNA-dependent transcription’’ and
the HGG-associated as ‘‘neuroactive ligand-receptor interaction’’, ‘‘neuronal cell body’’ and ‘‘defense response to bacterium’’.
Conclusion: LGG and HGG appear to have different molecular signatures in genomic variations and our results provide
invaluable information for the diagnosis and treatment of gliomas in patients with variable duration or diverse tumor
differentiation.
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Introduction
Glioma is a major tumor type that derives from glial cells of the
central nerve system, including of spine and the brain. Gliomas are
classified into four grades, from I to IV, with increasing
exacerbation according to histology [1]. Alternatively, they are
categorized into ependymomas, astrocytomas, oligodendroglio-
mas, and mixed gliomas, according to the cell types that are
anatomically defined from different brain regions based on the
brain topology [2]. Glioma is considered as low prevalence but an
increasing detection probability due to enhanced early detection
techniques and procedures, which include X-ray, magnetic
resonance imaging (MRI), and computed tomography (CT) [3].
Patients with gliomas often have a morbid state in various degrees,
including pain, epilepsy, mental disorder, visual disturbance,
hearing impairment, insomnia, and nausea [4]. Traditional
therapies for the tumors, such as surgery, radiotherapy, chemo-
therapy, and oral medication, are often individually or selectively
cooperated to remit or to cure the symptoms according to patient’s
condition and tumor grade [5,6].
Although the degree of copy number variations (CNVs) among
healthy human populations do vary, abnormal increase of CNVs
and cnLOHs are thought to be at least one of the important
causative factors for gliomas and other cancers [7,8,9]. Large-scale
genomic aberration and gene expression studies on gliomas have
lead to identifications of genes, which are involved in numerous
cellular functions and metabolic pathways (PCDH9, CXCL12,
MYC, PDGFRA, PARK2, DMBT1, TOP2A, PTEN, ARF, TP53,
P16, CDKN2B, RB1, EGFR, and NF1 [9,10,11,12,13,14,15,16,17]),
as well as those related to neural development, cell signaling
(RAS/RAF, RTK, MAPK, PI3K, and ROCK), and tumor
suppression (p53 and RB)
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[1,6,11,16,18,19,20,21,22,23,24,25,26,27,28]. These genes serve
as biomarkers useful for tumor classification, prognosis, and
targeted therapies [17,23,29,30,31,32,33,34].
Previous studies have been adding complexity for the un-
derstanding of gliomas at molecular levels. First, both nuclear and
mitochondrial genomes show numerous structural variations [35].
Second, there are heterogeneous patterns of structural variations
and/or expressions depending on the ways of classifying and
grading gliomas, even between primary and secondary gliomas
and between pediatric and adult gliomas [14,20,36,37]. Third,
consistency of the experimental results at DNA, RNA, and protein
levels is poor due to complications of transcriptional and post-
translational regulations, as well as enzymatic modifications
[6,12,38,39]. Fourth, relationship between sequence variations
and prognosis are influenced by certain patient-specific parame-
ters. For instance, older patients tend to have shorter survival time
than younger patients [1,40]. Fifth, co-variations can occur in
different chromosomes and one gene may have multiple variations
in different combinations [41,42]. Last, relatively homogenous
DNA variations have been found when topological locations (e.g.,
central vs. peripheral) are compared, where cross-contamination
between normal and tumor tissues may contribute to the incorrect
detection of structural variations [6,43,44]. Nevertheless, the
existing literature related to genomic alterations and their
molecular mechanisms in gliomas lacks information from Chinese
populations.
Together with increasing throughput and efficiency of sequenc-
ing and microarray technologies for SNP and CNV discovery and
typing, in-depth study on special tumor types become feasible,
especially when two novel parameters–physical (Log R ratio) and
genetic (B allele frequency) alterations/variability–are used to
increase sensitivity and accuracy [45]. We report the first study in
which we compared chromosomal aberrations of low-grade and
high-grade gliomas (LGG and HGG) in Chinese populations to
unveil differences of tumor-related sequence variations, including
chromosomes and cytobands, and individual genes in the context
of pathways and function categories.
Materials and Methods
Ethics Statement
This study was approved by the ethics committee at First
Hospital of Jilin University, and all patients who agreed to this
study signed their informed consents. In particular, some of the
written informed consents were also obtained from the next of kin,
caretakers, or guardians on the behalf of the minors/children
participants involved in this study.
Sample Preparation and Genotyping
18 gliomas, including nine of each for both low-grade (grade II)
and high-grade (6 grade III and 3 grade IV) tumors (as LGG and
HGG), as well as 18 paired blood samples were collected at First
Hospital of Jilin University (Table 1). In general, patients with
LGG (average age of 41) and HGG (average age of 47) have no
prior history of chemotherapy or radiation treatment, and the
tumors and matched peripheral blood samples were obtained at
the time of tumor resection. The blood samples were immediately
snap-frozen in liquid nitrogen and stored at 280uC before DNA
extraction. Portions of the solid tumors were treated in the same
way as the blood samples and others were paraffin-embedded for
histopathology. The genomic DNA was isolated by using QIAamp
DNA Mini Kit (QIAGEN Inc). DNA quality and purity were
determined based on agarose gel electrophoresis and spectropho-
tometry. Four additional gliomas for RNA RT-qPCR validation
were also collected at the same hospital and treated according to
the same protocol as used for the other samples (Table 1).
Genotyping was carried out by using Illumina Sentrix Human
Table 1. Overview of samples used in this study.
ID Gender Age Type of glioma Grade
Type of
experiment
S1 Male 40 astrocytoma II Chip
S2 Female 13 diffuse astrocytoma II Chip
S3 Male 37 diffuse astrocytoma II Chip
S4 Male 44 diffuse astrocytoma II Chip
S5 Female 33 diffuse astrocytoma II Chip
S6 Male 48 diffuse astrocytoma II Chip
S7 Female 32 medulloblastoma II Chip
S8 Female 63 oligodendroglioma II Chip
S9 Male 55 oligodendroglioma II Chip
S10 Male 37 anaplasia oligodendroglioma III Chip
S11 Female 55 anaplastic astrocytoma III Chip
S12 Male 57 anaplastic astrocytoma III Chip
S13 Female 43 anaplastic astrocytoma III Chip
S14 Male 39 anaplastic astrocytoma III Chip
S15 Female 55 astrocytoma III Chip
S16 Female 41 glioblastoma IV Chip
S17 Female 55 glioblastoma IV Chip
S18 Male 44 mixed oligodendroglioma IV Chip
S19 Male 39 anaplasia oligodendroglioma II RT-qPCR
S20 Male 7 medulloblastoma III RT-qPCR
S21 Male 11 glioblastoma IV RT-qPCR
S22 Female 59 glioblastoma IV RT-qPCR
Note: RT-qPCR: real-time quantitative PCR.
doi:10.1371/journal.pone.0057168.t001
Table 2. Primers and results of real-time qPCRs.
Gene Primer
Product size
(bp)
Fold
change
AASS F: AGCGCTACATAAGTCGTT 197 1.86
R: GTCACATATTGCCACGAGTTT
CYP2J2 F: AAAGAAGCCCTTATCCAC 187 30.53
R: GAATGCGTTCCTCTAAGCTCT
CYP4A11 F: CCTGGACCAGATGCCCTACAC 107 111.92
R: CAGGGAAGGTGACGGGAGT
PLA2G2A F: CATGATCTTTGGCCTACTGC 108 6.57
R: CAGCCGTAGAAGCCATAACTG
PLA2G5 F: ACATTCGCACACAGTCCTAC 170 24.23
R: GAGGATGTTGGGAAAGTATTG
PTEN F: CAGAAAGACTTGAAGGCGTAT 124 52.53
R: TTGGCGGTGTCATAATGT
RB1 F: TCCTCGAAGCCCTTACAAGTT 176 6.38
R: TCTCAGAAGTCCCGAATGAT
Note: These primers were designed by using Oligo6. Fold changes were
computed by comparing between HGG and LGG.
doi:10.1371/journal.pone.0057168.t002
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CNV370-Quad v3 BeadChip according to the manufacturer’s
instruction.
Data Analysis and Functional Annotation
Illumina’s KaryoStudio (V1.0.3), together with the cnvPartition
algorithm, was adopted to identify CNV regions. Illumina’s
GenomeStudio software (V2009.1) with LOHscore plug-in was
used to discover copy neutral loss of heterozygosity (cnLOH)
regions. The samples were divided into LGG and HGG, and the
analysis was limited to autosomal regions only due to the
experiment design. The data used in this study were submitted
to GEO with an accession of GSE34888.
GeneCoDis3 was used to relate genes to the corresponding
Gene Ontology (GO) terms with cut-off = 0.05 [46], and
WebGestalt V2 was used to map genes onto significant KEGG
pathways with cut-off = 0.1 [47]. OMIM (Online Mendelian
Inheritance in Man) was used to find relationship between genes
and diseases [48].
Real-time qPCR-based Validation Experiment
Four RNA samples, reverse-transcribed (Table 1), were
subjected to real-time qPCR in a final reaction volume of 10 ml,
which contains: 1 ml of 106buffer, 0.25 ml of dNTP, 2 ml of gene-
specific forward and reverse primer mix (Table 2), 1 ml cDNA
(100 ng/ml), 0.1 ml of rTaq, 0.5 ml of fluorochrome (TIANGEN
BIOTECH) and 5.15 ml of ddH2O.
Results
Case and Control
Using 18 solid tumors from patients (9 as LGG and 9 as HGG)
as the case sample and the patients’ DNA isolated from their
peripheral blood as the control, we compared chromosome
aberrations between the case and control based on the Illumina’s
BeadChip platform that defines both copy number variation
(CNVs) and copy neutral loss of heterozygosity (cnLOH). This
technology allows us to find sequence differences between tumor
and blood samples at cytogenetic and molecular levels, which
include both gains and losses. We only discovered sequence
amplifications in the tumor not in the corresponding periphery
blood. In other three aberration categories of CNVs, there are
always more variations in the tumor than in the control, and the
significance of variations between the paired samples can be
evaluated statistically (P-value,0.05, paired t-test) when the total
length influenced by CNVs in each sample was considered.
CNVs among Autosomal Arms
After the survey of different CNVs in 44 autosomal arms in
LGG and HGG, we removed those shared by tumors and their
controls to identify tumor-specific variations. We made a few
interesting observations. First, 13q harbors a major high-frequency
genomic aberration class. For instance, there are 3, 3, 3, 2, and 2
samples found to have homozygous deletion, hemizygous deletion,
cnLOHs, duplication and amplification, respectively. Second, we
found that 22, 29, 38, 38, and 6 chromosomal arms have
variations in the five categories, respectively. Obviously, cnLOH is
one of the most frequent categories, and our results agreed with
a previous report [43]. In addition, the skewed distribution of
sequence amplification showed that there were more copy number
gains found on only a few chromosomal arms. Third, we paid
more attention to CNVs between LGG and HGG and found
several homozygous deletions of 13q in HGG but not in LGG.
There were also cnLOHs in three HGG, such as those on 15q and
17q, but none was found in LGG. In addition, four HGG had
duplications on 3q but none was found in LGG.
Comparison of LGG and HGG at the Cytoband Level
To pinpoint the position of variations on chromosomes, we
investigated CNV and cnLOH in LGG and HGG. To reduce
false positives, we only referred to those that occurred in at least
two tumor samples (four samples for ‘‘duplications’’ category) after
removing what appeared in the controls, i.e., corresponding blood
samples (Table 3). Taking homozygous deletion as an example, we
found several events on 8p11.23 in LGG, and 13q12.11 in HGG.
In both hemizygous deletion and cnLOH, we found more
cytobands in HGG than in LGG. Surprisingly, we found more
Table 3. Comparison of sample numbers of genomic
aberration in gliomas at the cytoband level.
Homozygous
deletions
L 8p11.23 2
H 13q12.11 2
Hemizygous deletions L 5q14.3 2 11q11 2
H 6q12 2 6q13 2 6q14.1 2
H 6q14.2 2 6q14.3 2 6q16.3 2
H 6q21 2 6q22.1 2 6q22.31 2
H 6q22.32 2 6q22.33 2 6q23.1 2
H 6q23.2 2 6q23.3 2 6q24.1 2
H 6q24.2 2 11p15.4 2 13q12.2 2
H 13q12.3 2 13q13.1 2 13q13.2 2
H 13q14.12 2 13q14.13 2 13q14.2 2
H 13q14.3 2 13q21.1 2 13q21.2 2
H 13q21.31 2 19q12 2 19q13.11 2
H 19q13.12 2
cnLOHs L 2p12 2 6p21.32 2 6p21.33 2
L 6p22.1 2 6q15 2 9p24.1 2
L 22q12.3 2
H 2p23.2 2 2p25.1 3 2p25.3 2
H 3q26.1 2 6p21.32 3 6p21.33 3
H 6q25.1 2 8q22.3 2 8q24.3 3
H 9p24.1 2 9p24.2 2 10p13 2
H 10p15.1 2 14q32.13 2 15q26.1 2
H 17p13.3 2 17q22 2 18q22.1 2
H 18q22.3 2 18q23 2 21q22.3 2
H 22q13.31 3
Duplications L 1p13.3 4 1p21.1 4 1p21.3 4
L 1p22.2 4 1p22.3 4 1p31.1 4
L 1p31.3 4 1p32.1 4 1p32.2 4
L 1p32.3 4 1p33 4 1p34.3 4
L 1p35.1 4 1p35.2 4 1p35.3 4
L 1p36.11 4 1p36.12 4 1p36.13 4
L 1p36.31 4
H 5p15.33 4 7q31.31 4 7q31.32 4
H 7q31.33 4 7q33 4 7q34 4
H 7q35 4 7q36.1 4 20q11.1 4
Amplifications H 7p11.2 2
Note: L and H stand for LGG and HGG, respectively.
doi:10.1371/journal.pone.0057168.t003
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duplication events in LGG than in HGG. Taken together, we
conjectured that losses and gains occur more often in HGG and
LGG, respectively. Furthermore, we found that gains usually
occurred on 7q and 1p in HGG and LGG, respectively.
Decreasing copy number is usually discovered on 6q, 13q and
19q in HGG. We also noticed that there were overlaps between
the two tumor grades in the cnLOH category, especially the fact
that cnLOHs were spread out more broadly in cross-chromosome
cytobanding than the rest of copy number variation categories.
Genes Found to Associate with Gliomas
To identify specific genes associated with gliomas, we pooled all
genomic aberrations occurred in at least six tumor samples. After
filtered our data based on known variations found in the controls
and Database of Genomic Variants (hg18.v8) (http://projects.
tcag.ca/variation/), we had 24 genes and the related information
was summarized (chromosome location, aberration category,
tumor grading) (Table 4). These genes are all clustered on 1p,
7q, and 19q. Among them, 17 genes are only gains, and three of
other genes, VN1R2, VN1R4 and ZNF677, have all three types of
genomic aberrations–gain, loss and cnLOH. Referencing to the
annotation of the OMIMMorbid Map (http://www.ncbi.nlm.nih.
gov/omim), we found that AASS, TAS2R16 and TSPAN12 are
previously identified to be disease-related and associated with
‘‘hyperlysinemia’’, ‘‘alcohol dependence’’ and ‘‘exudative vitreoretinopathy’’,
respectively.
Pathway Enrichment and Functional Annotation of the
Associated Genes
To decipher functional relevance of genes and gene classifica-
tion related to gliomas, we established datasets based on the
following two criteria: (i) elimination of genes shared by both the
case and the control and (ii) removal of genes shared by less than
four samples. Altogether, we collected 442 LGG and 111 HGG
associated genes. After mapping the two groups of genes onto the
KEGG pathways, we obtained 12 pathways for LGG, which
belong to ‘‘lipid metabolism’’ (in the number of pathways: 6),
‘‘neurodegenerative diseases’’ (1), ‘‘endocrine system’’ (1), ‘‘ner-
vous system’’ (1), ‘‘circulatory system’’ (1), ‘‘signal transduction’’
(1), and ‘‘immune system’’ (1) (Table 5). These genes were
categorized in 10 pathways correlated to HGG, among which two
were classified as ‘‘lipid metabolism’’ and others were distributed
in diverse classifications such as ‘‘signaling molecules and in-
teraction’’, ‘‘signal transduction’’, ‘‘endocrine system’’, ‘‘carbohy-
drate metabolism’’, ‘‘amino acid metabolism’’, ‘‘glycan biosynthe-
sis and metabolism’’, and ‘‘infectious diseases’’. The most four
significant pathways identified in LGG are ‘‘arachidonic acid
metabolism’’, ‘‘linoleic acid metabolism’’, ‘‘alpha-Linolenic acid metabolism’’,
and ‘‘ether lipid metabolism’’. In HGG, the most four enriched terms
are ‘‘metabolic pathways’’, ‘‘neuroactive ligand-receptor interaction’’, ‘‘cal-
cium signaling pathway’’, and ‘‘melanogenesis’’. We found 12 and 4
enriched GO terms associated with LGG and HGG, respectively
(Table 6). In LGG, the top two GO terms were ‘‘DNA binding’’, and
‘‘regulation of transcription, DNA-dependent’’. In HGG, the top two GO
terms were ‘‘neuronal cell body’’, and ‘‘defense response to bacterium’’. To
Table 4. Selected genes involved in genomic aberration of gliomas.
Gene Description Location Total Gain Loss cnLOH LGG HGG
NKAIN1 Na+/K+ transporting ATPase interacting 1 1p 6 5 1 4 2
PTPRU Protein tyrosine phosphatase, receptor type, U 1p 6 5 1 4 2
SLC44A3 Solute carrier family 44, member 3 1p 6 5 1 4 2
AASS Aminoadipate-semialdehyde synthase 7q 6 6 2 4
ASB15 Ankyrin repeat and SOCS box-containing 15 7q 6 6 2 4
C7orf58 chromosome 7 open reading frame 58 7q 6 6 2 4
FEZF1 FEZ family zinc finger 1 7q 6 6 2 4
GPR37 G protein-coupled receptor 37 (endothelin receptor type B-like) 7q 6 6 2 4
HYAL4 Hyaluronoglucosaminidase 4 7q 6 6 2 4
ING3 Inhibitor of growth family, member 3 7q 6 6 2 4
IQUB IQ motif and ubiquitin domain containing 7q 6 6 2 4
LMOD2 Leiomodin 2 (cardiac) 7q 6 6 2 4
NDUFA5 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5, 13 kDa 7q 6 6 2 4
POT1 POT1 protection of telomeres 1 homolog (S. pombe) 7q 6 6 2 4
RNF133 Ring finger protein 133 7q 6 6 2 4
RNF148 Ring finger protein 148 7q 6 6 2 4
SPAM1 Sperm adhesion molecule 1 7q 6 6 2 4
TAS2R16 Taste receptor, type 2, member 16 7q 6 6 2 4
TSPAN12 Tetraspanin 12 7q 6 6 2 4
WASL Wiskott-Aldrich syndrome-like 7q 6 6 2 4
VN1R2 Vomeronasal 1 receptor 2 19q 6 4 1 1 5 1
VN1R4 Vomeronasal 1 receptor 4 19q 6 4 1 1 5 1
ZNF507 Zinc finger protein 507 19q 6 3 3 4 2
ZNF677 Zinc finger protein 677 19q 6 4 1 1 5 1
doi:10.1371/journal.pone.0057168.t004
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our current knowledge, tumors often alter cellular processes, such
as proliferation, growth, programmed death, differentiation,
division, mutation-induced DNA damage, and repair [1]. All
these newly discovered distinct function categories may introduce
features of primary (low-grade) or malignant (high-grade) tumors.
Correlating Copy Number Variation with Gene Expression
We used real-time qPCR to validate the expression of seven
identified genes: AASS, CYP2J2, CYP4A11, PLA2G2A, PLA2G5,
PTEN, and RB1. First, all genes showed increased expression when
compared in the two tumor grades (HGG vs. LGG) (Table 2).
CYP2J2, CYP4A11, PLA2G5 and PTEN exhibited even over 10
fold changes. We did not compare the gene expressions between
the tumors and the controls, their corresponding blood cells, due
to the tissue-specific nature of the gene expression. Of the seven
genes, we noticed RB1 gains in HGG and losses in both grades.
Other different aberrations include (1) CYP2J2, CYP4A11,
PLA2G2A, and PLA2G5 gains in LGG, (2) AASS gain in both,
and (3) PTEN gains in HGG only. The correlation between
expression and copy number is complex, and has been demon-
strated to be positive under most conditions with several
exceptions of negative correlations [12]. There are a few
interpretations for the complicated relations between gene (or
segment) copy number and gene expression. First, the higher gene
dosage leads to an increased transcript production and a positive
correlation. Second, negative correlation has been proposed that
some possible compensation or time-series feedback effects may
act on the progression or cell response of tumors [12]. Last,
a handful of CNVs can destroy regulatory regions to some extents
and inhibit the expression of relevant genes. In any case, we have
found significant differential gene expressions in selected genomic
structures and genes between LGG and HGG.
Discussion
In accordance with Knudson’s two-hit hypothesis on tumor
formation [49], tumorigenesis occurs concurrently with activation
of oncogenes and inactivation of tumor suppressor genes (TSGs).
In particular, tumor formation is a process where the potential for
malignancy increases with mutation accumulation [50]. Our
results support the concept that genomes in HGG tend to be
deleted more intensively than those in LGG at both cytoband and
molecular levels. In other words, there are gains of genes or partial
sequences in the primary stage of the tumors and subsequently
losses of tumor suppressor genes or TSGs appear to escape from
normal cellular controls. For instance, cnLOHs in HGG
happened in twelve chromosomes (2, 3, 6, 8, 9, 10, 14, 15, 17,
18, 21, and 22). In contrast, cnLOHs in LGG occurred only in
Table 5. Pathway analysis of genes involved in genomic aberration in LGG (A) and HGG (B).
(A) LGG
Pathway name Observed number Expected number R FDR
Arachidonic acid metabolism 9 1.35 6.69 1.00E204
Linoleic acid metabolism 7 0.67 10.41 1.00E204
alpha-Linolenic acid metabolism 6 0.43 13.87 1.00E204
Ether lipid metabolism 7 0.82 8.57 2.00E204
Glycerophospholipid metabolism 8 1.61 4.97 2.10E203
Prion diseases 6 0.84 7.14 2.10E203
GnRH signaling pathway 9 2.38 3.78 5.50E203
Long-term depression 7 1.63 4.28 9.60E203
Vascular smooth muscle contraction 9 2.71 3.32 1.14E202
VEGF signaling pathway 7 1.78 3.94 1.28E202
Fc epsilon RI signaling pathway 7 1.85 3.78 1.45E202
Fatty acid metabolism 4 1.01 3.96 9.55E202
(B) HGG
Pathway name Observed number Expected number R FDR
Metabolic pathways 14 6.21 2.25 6.00E202
Neuroactive ligand-receptor interaction 5 1.48 3.37 6.00E202
Calcium signaling pathway 4 1.02 3.92 6.00E202
Melanogenesis 3 0.58 5.14 6.00E202
Fructose and mannose metabolism 2 0.2 10.08 6.00E202
Lysine degradation 2 0.25 7.97 6.00E202
Androgen and estrogen metabolism 2 0.26 7.62 6.00E202
Glycerolipid metabolism 2 0.25 7.97 6.00E202
Glycosaminoglycan degradation 2 0.12 16.32 6.00E202
Vibrio cholerae infection 2 0.31 6.47 7.28E202
Note: R indicates the ratio of enrichment.
doi:10.1371/journal.pone.0057168.t005
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four chromosomes (2, 6, 9, and 22) (Table 3). This particular clear
observation in cnLOHs has not been found in other variation
types, and the result indicates that disappearance of heterozygosity
and allelic losses together with gene functions are major
contributors to HGG.
We have effectively validated many locations, genes, pathways,
and function categories in keeping with the previous studies at
different levels. At the chromosome level, among the five variation
classes, cnLOH is the major type, which is distributed over all
chromosomes. Furthermore, we have validated many variations at
the cytoband level (Table 3). For instance, we found duplications
on 7q31.31, 7q31.32, 7q31.33, 7q33, 7q34, 7q35 and 7q36.1 in
HGG, which is in agreement with gains of 7q reported in both
grades [37]. We discovered hemizygous deletions on numerous
cytobands (e.g., 6q12, 6q13, 6q14.1, 6q16.3, 6q21, 6q22.1,
6q23.1, 6q24.1, 13q12.2, 13q13.1, 13q14.12, 13q21.1, 19q12,
and 19q13.11) in line with losses of 6q, 13q, and 19q in HGG
[37,44]. There have been some contradicting results in this study;
for example, we only identified duplications on 1p in LGG and
hemizygous deletions on 19q in HGG but LOHs on 1p-19q were
reported in both grades by another group [41]. We also have some
novel findings specific to Chinese populations and observed the
complicated and altered roles of traditional tumor-related genes in
our study. For example, KIT gains in 2 LGG and 2 HGG, MGMT
gains in 1 LGG and 3 HGG, MXI1 gains in 1 LGG and 3 HGG,
DMBT1 gains in 1 LGG and 3 HGG, IDH1 only gains in one
LGG. Thus, TSGs and oncogenes are relative and condition-
sensitive concept, i.e., TSGs in one sample may be oncogenes in
another. We finally inferred that TSGs not only can be lost but
also can be gained, whereas oncogenes appear generally being
gained in these tumors.
We did not find any obvious major pathways shared by LGG
and HGG but identified 6 and 2 subclasses from the major class
‘‘lipid metabolism’’ shared by the two grades, respectively. In HGG,
we noticed some interesting variations, including AASS (4 gains) in
‘‘lysine degradation’’ and CHRM2 (4 gains), CYSLTR2 (2 gains and 2
losses), GRM8 (4 gains), HTR2A (2 gains and 2 losses), and MLNR
(2 gains and 2 losses) in ‘‘neuroactive ligand-receptor interaction’’. We
further found variations of GRM8 (2 gains) and CYSLTR2 (1 loss),
HTR2A (1 loss),MLNR (1 loss) in LGG. Gains in the four LGG are
CYP2J2, CYP4A11, CYP4A22, PLA2G2A, PLA2G2C, PLA2G2D,
PLA2G2E, PLA2G2F, and PLA2G5, and they are involved in
‘‘arachidonic acid metabolism’’. Looking into well-known oncogenes
and TSGs, we identified gains of EGFR in ‘‘de novo glioma pathway’’
(2 in LGG and 3 in HGG), as well as MDM2 (1 in LGG and 3 in
HGG) and PTEN (1 in HGG), and losses of CDKN2A (2 in HGG).
In ‘‘secondary glioma pathway’’, gains of PDGFA (1 in LGG and 2 in
HGG), PDGFRA (2 in LGG and 2 in HGG) and CDK4 (1 in LGG
and 2 in HGG) and RB1 (2 in HGG), and losses of RB1 (1 in LGG
and 2 in HGG) are also identified.
Our study was designed to uncover molecular differences
between LGG and HGG, which are largely based on pathology,
morphology, and degree of malignancy, and for which we know
that altered genomic regions of HGG are more severe than those
of LGG and that patient survival time is shorter in HGG (data not
shown). Based on our study, we hope to associate genetics to
clinical outcomes in three crucial aspects of fighting the disease,
including diagnosis, treatment, and prognosis. First, specific and
Table 6. GO enrichment analysis of genes involved in genomic aberration in LGG (A) and HGG (B).
(A) LGG
GO term Description NG NGR Hyp*
GO:0003677 DNA binding (MF) 104 1651 5.89E218
GO:0006355 regulation of transcription, DNA-dependent (BP) 95 1473 2.27E216
GO:0008270 zinc ion binding (MF) 103 1780 2.16E215
GO:0005622 intracellular (CC) 100 1774 4.42E214
GO:0046872 metal ion binding (MF) 120 2649 1.39E210
GO:0003676 nucleic acid binding (MF) 42 721 1.11E205
GO:0006644 phospholipid metabolic process (BP) 8 31 2.35E204
GO:0016503 pheromone receptor activity (MF) 3 3 9.58E204
GO:0019236 response to pheromone (BP) 3 3 4.16E203
GO:0004623 phospholipase A2 activity (MF) 5 20 5.27E203
GO:0005634 nucleus (CC) 156 4968 6.35E203
GO:0019205 nucleobase-containing compound kinase activity (MF) 3 7 2.23E202
(B) HGG
GO term Description NG NGR Hyp*
GO:0043025 neuronal cell body (CC) 9 205 4.00E204
GO:0042742 defense response to bacterium (BP) 6 81 3.41E203
GO:0015382 sodium:sulfate symporter activity (MF) 2 2 5.95E203
GO:0004415 hyalurononglucosaminidase activity (MF) 2 6 4.39E202
Note:
NG=Number of annotated genes in the inquired list.
NGR=Number of annotated genes in the reference list.
Hyp* = Corrected hypergeometric P-value.
doi:10.1371/journal.pone.0057168.t006
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dominant genomic variations in cytobands or genes may be used
to classify the two tumor grades at molecular level. Second,
different genes with DNA aberrations may be further pursued as
potential drug targets, especially in the personalized or population-
specific cancer treatment for Chinese populations. Third, the
disease-associated genes from LGG and HGG may be used for
inferring survival time and guidance for disease treat [51,52,53].
In addition, we proposed a theory that losses of genes or alleles
may play greater role in the formation and progression of HGG
although both gains and losses contribute. This phenomenon is
only observed at the cytoband level and relevant to concentrated
alternations of homologous or heterogeneous genome composition
[54]. Therefore, this is not a decisive but a substantial measure for
glioma morbidity. Further large-scale investigations are needed for
further validations.
Ultimately, we should be able to build an intricate network that
is composed of pathways involved in gliomas both identified in this
study and other known in the previous literature as we exemplified
in Figure 1. The first characteristic of the network is the difficulty
to fully discriminate all three complex modules of the pathways,
such as LGG, HGG and others. However, we are able to identify
major hubs among the modules, such as MP and MAPK, in the
categories of HGG and others, respectively; some may even be
obviously LGG associated, such as AAM. In addition, the tissue-
specificity of gliomas is blurred by AP and other five vertices
including PD, ALS, AD, HUD and PAD, which are common for
neurodegenerative diseases and other neuro-pathological condi-
tions. As a final note, the patterns of the three categories may
suggest that there are differences in disease-causing mechanisms
between Chinese and other populations. It is undoubted that
studies on larger samples, coupled with in-depth analyses and
validations, are what we should do in the near future.
Figure 1. A network of pathways related to LGG, HGG, and others. The abbreviations for KEGG pathways used in this analysis are listed as
follows. AAM: Arachidonic acid metabolism; LAM: Linoleic acid metabolism; ALAM: alpha-Linolenic acid metabolism; ELM: Ether lipid metabolism;
GPM: Glycerophospholipid metabolism; PD: Prion diseases; GNRH: GnRH signaling pathway; LTD: Long-term depression; VSMC: Vascular smooth
muscle contraction; VEGF: VEGF signaling pathway; FCER: Fc epsilon RI signaling pathway; FAM: Fatty acid metabolism; MP: Metabolic pathways; NLI:
Neuroactive ligand-receptor interaction; CSP: Calcium signaling pathway; ME: Melanogenesis; FMM: Fructose and mannose metabolism; LD: Lysine
degradation; AEM: Androgen and estrogen metabolism; GM: Glycerolipid metabolism; GD: Glycosaminoglycan degradation; VCI: Vibrio cholerae
infection; AD: Alzheimer’s disease; PAD: Parkinson’s disease; ALS: Amyotrophic lateral sclerosis; HUD: Huntington’s disease; PI3K: PI3K-Akt signaling
pathway; HIF-1: HIF-1 signaling pathway; MAPK: MAPK signaling pathway; CC: Cell cycle; P53: p53 signaling pathway; AP: Apoptosis; GL: Glioma; ERBB:
ErbB signaling pathway; WNT: Wnt signaling pathway; and OP: Oxidative phosphorylation.
doi:10.1371/journal.pone.0057168.g001
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